Dare Bioscience Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 2834 https://www.darebioscience.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dare Bioscience Inc

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - Aug 26th, 2024 12:00 pm
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% - Aug 13th, 2024 12:00 pm
Dare Bioscience, Inc. (DARE) Q2 Earnings Top Estimates - Aug 12th, 2024 9:15 pm
Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update - Aug 12th, 2024 8:01 pm
Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 - Aug 5th, 2024 12:00 pm
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - Jul 19th, 2024 12:00 pm
Daré Bioscience Announces Reverse Stock Split - Jun 27th, 2024 12:00 pm
Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder - Jun 24th, 2024 12:00 pm
Q1 2024 Dare Bioscience Inc Earnings Call - May 15th, 2024 4:27 pm
Dare Bioscience Inc (DARE) (Q1 2024) Earnings Call Transcript Highlights: Strategic Moves Amid ... - May 15th, 2024 7:13 am
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update - May 14th, 2024 12:00 pm
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 - May 7th, 2024 12:00 pm
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network - May 2nd, 2024 12:00 pm
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts - Apr 30th, 2024 11:30 am
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - Apr 23rd, 2024 12:00 pm
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive - Apr 11th, 2024 12:00 pm
Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Call Transcript - Apr 1st, 2024 8:05 pm
Q4 2023 Dare Bioscience Inc Earnings Call - Mar 29th, 2024 1:07 pm
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update - Mar 28th, 2024 12:00 pm
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024 - Mar 21st, 2024 12:00 pm